Sage Therapeutics said Wednesday its Biogen-partnered treatment for essential tremor failed in a Phase 2 study, leading Sage stock to collapse. Please watch the video at Investors.com - How To ...

Sage Therapeutics is rated a Strong Buy due to its undervaluation, trading below cash holdings, and potential in its drug pipeline, especially Zuranolone. Biogen's $7.22 per share buyout offer ...

Shares of Sage Therapeutics Inc. fell more than 20% premarket on Wednesday after a failed trial dealt a blow to the company’s collaboration with Biogen Inc. Sage and Biogen announced Wednesday ...

Vanessa Leroy / Bloomberg via Getty Images Sage Therapeutics reported that Biogen made an unsolicited offer to purchase all of the shares of the biopharmaceutical firm it doesn't already own.

Biogen and Sage Therapeutics are discontinuing further development of their drug Zurzuvae as a potential treatment for major depressive disorder, a move that follows last year’s FDA rejection of ...

Sage Therapeutics (SAGE ... nonbinding proposal it received from Biogen (BIIB) on January 10 to acquire all outstanding shares of Sage not already owned by Biogen for $7.22 per share.

SAGE Therapeutics ( (SAGE)) has shared an announcement. Biogen has informed Sage Therapeutics of its decision to terminate their collaboration on the SAGE-324 molecule, effective February 17 ...

Head of Therapeutics Development Unit, Biogen. KINETIC 2 Study Results The KINETIC 2 Study was designed to evaluate the dose-response relationship of different doses of SAGE-324 on upper limb tremor.

On Thursday, Sage Therapeutics Inc. (NASDAQ:SAGE) announced that Biogen Inc (NASDAQ:BIIB) had terminated its rights under the collaboration and license agreement with Sage, which was specific to ...

Sage Therapeutics (SAGE) said Biogen (BIIB) has made an unsolicited offer to acquire the rest of SAGE shares. Biogen currently owns a 10.2% stake in Sage Therapeutics; SAGE board members will ...